{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:32:26Z","timestamp":1775151146118,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.jval.2012.09.006","type":"journal-article","created":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T12:20:14Z","timestamp":1358598014000},"page":"66-75","source":"Crossref","is-referenced-by-count":9,"title":["A Quantitative Benefit-Risk Analysis of Isoniazid for Treatment of Latent Tuberculosis Infection Using Incremental Benefit Framework"],"prefix":"10.1016","volume":"16","author":[{"given":"Mohsen","family":"Sadatsafavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fawziah","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onofre","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Mark","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Lynd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2012.09.006_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJM200107193450307","article-title":"Management of tuberculosis in the United States","volume":"345","author":"Small","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.09.006_bib2","first-page":"1185","article-title":"Tuberculosis: 3, epidemiology of the disease in Canada","volume":"160","author":"Long","year":"1999","journal-title":"CMAJ"},{"key":"10.1016\/j.jval.2012.09.006_bib3","unstructured":"Center for Disease Control and Prevention. Trends in tuberculosis\u2014United States, 2005. MMWR Morb. Mortal Wkly Rep 2006 Mar 24;55:305\u20138."},{"key":"10.1016\/j.jval.2012.09.006_bib4","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"American Thoracic Society","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jval.2012.09.006_bib5","unstructured":"Canadian Tuberculosis Standards\u20146th Edition 2007\u2014Public Health Agency of Canada. 2010. Available from: http:\/\/www.phac-aspc.gc.ca\/tbpc-latb\/pubs\/tbstand07-eng.php. [Accessed April 28, 2012]."},{"key":"10.1016\/j.jval.2012.09.006_bib6","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0140-6736(09)60559-6","article-title":"Fourth-generation fluoroquinolones in tuberculosis","volume":"373","author":"Rieder","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2012.09.006_bib7","first-page":"371","volume":"110","year":"1974","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jval.2012.09.006_bib8","first-page":"790","volume":"127","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jval.2012.09.006_bib9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/pds.887","article-title":"Benefit-risk analysis: a proposal using quantitative methods","volume":"12","author":"Holden","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jval.2012.09.006_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0272989X08323299","article-title":"A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives","volume":"29","author":"Felli","year":"2009","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2012.09.006_bib11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.7326\/0003-4819-107-6-843","article-title":"Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons","volume":"107","author":"Stead","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2012.09.006_bib12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/sj.clpt.6100398","article-title":"Individualized medicine and the imperative of global health","volume":"82","author":"Waldman","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jval.2012.09.006_bib13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jclinepi.2003.12.012","article-title":"Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis","volume":"57","author":"Lynd","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jval.2012.09.006_bib14","first-page":"1014","article-title":"Tuberculin skin test size and risk of tuberculosis development: a large population-based study in contacts","volume":"11","author":"Mor\u00e1n-Mendoza","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jval.2012.09.006_bib15","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jval.2012.09.006_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1378\/chest.128.1.116","article-title":"Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic","volume":"128","author":"Fountain","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jval.2012.09.006_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jval.2012.09.006_bib18","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2012.09.006_bib19","first-page":"560","article-title":"Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis","volume":"159","author":"Salpeter","year":"1993","journal-title":"West J Med"},{"key":"10.1016\/j.jval.2012.09.006_bib20","first-page":"216","article-title":"Discussion of the paper by D. R. Cox","volume":"34","author":"Breslow","year":"1972","journal-title":"J R Statist Soc B"},{"key":"10.1016\/j.jval.2012.09.006_bib21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.09.006_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/0003-4819-84-2-181","article-title":"Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis","volume":"84","author":"Mitchell","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2012.09.006_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Toxic hepatitis with isoniazid and rifampin: a meta-analysis","volume":"99","author":"Steele","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.jval.2012.09.006_bib24","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","volume":"2","author":"Smieja","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jval.2012.09.006_bib25","first-page":"555","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jval.2012.09.006_bib26","unstructured":"ATS\/CDC Statement Committee on Latent Tuberculosis Infection Membership List. Targeted tuberculin testing and treatment of latent tuberculosis infection. 2000. Available from: http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr4906a1.htm. [Accessed April 28, 2012]."},{"key":"10.1016\/j.jval.2012.09.006_bib27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jval.2012.09.006_bib28","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1164\/ajrccm.162.5.2003028","article-title":"Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis","volume":"162","author":"Jasmer","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jval.2012.09.006_bib29","unstructured":"Statistics Canada. Life tables, Canada and provinces and territories. Available from: http:\/\/www.statcan.gc.ca\/pub\/84-537-x\/4064441-eng.htm. [Accessed April 28, 2012]."},{"key":"10.1016\/j.jval.2012.09.006_bib30","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1524-4733.2008.00355.x","article-title":"Health state utilities in latent and active tuberculosis","volume":"11","author":"Guo","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2012.09.006_bib31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1378\/chest.07-1494","article-title":"Health-related quality of life trajectories among adults with tuberculosis: differences between latent and active infection","volume":"133","author":"Marra","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jval.2012.09.006_bib32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archderm.1995.01690170063009","article-title":"Assessing the preferences of patients with psoriasis: a quantitative, utility approach","volume":"131","author":"Zug","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jval.2012.09.006_bib33","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hec.787","article-title":"An empirical comparison of EQ-5D and SF-6D in liver transplant patients","volume":"12","author":"Longworth","year":"2003","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2012.09.006_bib34","unstructured":"Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. Report No. 172chedp. York: Centre for Health Economics, University of York, 1999. Available from: http:\/\/ideas.repec.org\/p\/chy\/respap\/172chedp.html. [Accessed April 28, 2012]."},{"key":"10.1016\/j.jval.2012.09.006_bib35","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1183\/09031936.00159409","article-title":"Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis","volume":"36","author":"Guo","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jval.2012.09.006_bib36","first-page":"265","article-title":"Canadian normative data for the SF-36 health survey","volume":"163","author":"Hopman","year":"2000","journal-title":"CMA"},{"key":"10.1016\/j.jval.2012.09.006_bib37","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1524-4733.2008.00428.x","article-title":"Brazier J. Predicting the Short Form-6D preference-based index using the eight mean Short Form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available","volume":"12","author":"Ara","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2012.09.006_bib38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1477-7525-7-14","article-title":"Measuring health-related quality of life in tuberculosis: a systematic review","volume":"7","author":"Guo","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2012.09.006_bib39","first-page":"1100","article-title":"The assessment of patients\u2019 health-related quality of life during tuberculosis treatment in Wuhan, China","volume":"8","author":"Chamla","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jval.2012.09.006_bib40","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s11136-004-0374-1","article-title":"Quality of life in tuberculosis: a review of the English language literature","volume":"13","author":"Chang","year":"2004","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2012.09.006_bib41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/ije\/28.3.563","article-title":"Cost-effectiveness of screening compared to case-finding approaches to tuberculosis in long-term care facilities for the elderly","volume":"28","author":"Marchand","year":"1999","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jval.2012.09.006_bib42","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1377\/hlthaff.26.3.684","article-title":"Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis","volume":"26","author":"Garrison","year":"2007","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jval.2012.09.006_bib43","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1086\/647944","article-title":"4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity","volume":"49","author":"Ziakas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2012.09.006_bib44","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","article-title":"Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection","volume":"179","author":"Holland","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jval.2012.09.006_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diagmicrobio.2008.01.002","article-title":"Evaluation of the diagnostic utility of a whole-blood interferon-gamma assay for determining the risk of exposure to Mycobacterium tuberculosis in Bacille Calmette-Guerin (BCG)-vaccinated individuals","volume":"61","author":"Eum","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jval.2012.09.006_bib46","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/rccm.201101-0181OC","article-title":"Priorities for screening and treatment of latent tuberculosis infection in the United States","volume":"184","author":"Linas","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jval.2012.09.006_bib47","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","article-title":"Healthy user and related biases in observational studies of preventive interventions: a primer for physicians","volume":"26","author":"Shrank","year":"2011","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jval.2012.09.006_bib48","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/thorax.57.9.804","article-title":"A meta-analysis of the effect of Bacille Calmette Gu\u00e9rin vaccination on tuberculin skin test measurements","volume":"57","author":"Wang","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.jval.2012.09.006_bib49","first-page":"498","article-title":"Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results","volume":"12","author":"Menzies","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jval.2012.09.006_bib50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0169-5347(01)02144-9","article-title":"How should pathogen transmission be modelled?","volume":"16","author":"McCallum","year":"2001","journal-title":"Trends Ecol Evol"},{"key":"10.1016\/j.jval.2012.09.006_bib51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0167-6296(98)00039-3","article-title":"The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies","volume":"18","author":"Claxton","year":"1999","journal-title":"Health Econ Rev"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512041319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512041319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T11:31:17Z","timestamp":1539948677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301512041319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1098301512041319"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2012.09.006","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}